comparemela.com
Home
Live Updates
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference : comparemela.com
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion in cash, cash...
Related Keywords
China ,
Germany ,
United States ,
California ,
San Francisco ,
Ugur Sahin ,
Genmab Sa ,
Fosun Pharma ,
Roche Group ,
Biotheus Inc ,
Pfizer Inc ,
Duality Biologics Suzhou Co ,
Pfizer ,
Genentech Inc ,
Drug Administration ,
Genentech ,
Healthcare Conference ,
Investor Relations ,
Full Year ,
Fourth Quarter ,
Selected Pipeline Updates ,
Duality Biologics ,
Breakthrough Designation ,
Hormone Receptor Positive ,
Investigational New Drug ,
General Meeting ,
New Technologies ,
Private Securities Litigation Reform Act ,
Markets ,
comparemela.com © 2020. All Rights Reserved.